

## Research article

# HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies

Lukas Fenner<sup>1,2,3§</sup>, Andrew Atkinson<sup>4</sup>, Andrew Boule<sup>5</sup>, Matthew P. Fox<sup>6,7</sup>, Hans Prozesky<sup>8</sup>, Kathrin Zürcher<sup>1</sup>, Marie Ballif<sup>1</sup>, Hansjakob Furrer<sup>4</sup>, Marcel Zwahlen<sup>1</sup>, Mary-Ann Davies<sup>9</sup>, Matthias Egger<sup>1,9</sup>; for the International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA)

<sup>§</sup>Corresponding author: Lukas Fenner, Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland. Tel: +41 31 631 3505. (lukas.fenner@ispm.unibe.ch)

### Abstract

**Introduction:** Chronic immune activation due to ongoing HIV replication may lead to impaired immune responses against opportunistic infections such as tuberculosis (TB). We studied the role of HIV replication as a risk factor for incident TB after starting antiretroviral therapy (ART).

**Methods:** We included all HIV-positive adult patients ( $\geq 16$  years) in care between 2000 and 2014 at three ART programmes in South Africa. Patients with previous TB were excluded. Missing CD4 cell counts and HIV-RNA viral loads at ART start (baseline) and during follow-up were imputed. We used parametric survival models to assess TB incidence (pulmonary and extrapulmonary) by CD4 cell and HIV-RNA levels, and estimated the rate ratios for TB by including age, sex, baseline viral loads, CD4 cell counts, and WHO clinical stage in the model. We also used Poisson general additive regression models with time-updated CD4 and HIV-RNA values, adjusting for age and sex.

**Results:** We included 44,260 patients with a median follow-up time of 2.7 years (interquartile range [IQR] 1.0–5.0); 3,819 incident TB cases were recorded (8.6%). At baseline, the median age was 34 years (IQR 28–41); 30,675 patients (69.3%) were female. The median CD4 cell count was 156 cells/ $\mu\text{L}$  (IQR 79–229) and the median HIV-RNA viral load 58,000 copies/mL (IQR 6,000–240,000). Overall TB incidence was 26.2/1,000 person-years (95% confidence interval [CI] 25.3–27.0). Compared to the lowest viral load category (0–999 copies/mL), the adjusted rate ratio for TB was 1.41 (95% CI 1.15–1.75,  $p < 0.001$ ) in the highest group ( $>10,000$  copies/mL). Time-updated analyses for CD4/HIV-RNA confirmed the association of viral load with the risk for TB.

**Conclusions:** Our results indicate that ongoing HIV replication is an important risk factor for TB, regardless of CD4 cell counts, and underline the importance of early ART start and retention on ART.

**Keywords:** tuberculosis; HIV; antiretroviral treatment; viral load; CD4 cell count; time-updated; incidence; opportunistic infection; prediction

To access the supplementary material to this article please see Supplemental Files under Article Tools [online](#).

Received 20 October 2016; Accepted 7 June 2017; Published 23 June 2017

**Copyright:** © 2017 Fenner L et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) License (<http://creativecommons.org/licenses/by/3.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Introduction

In 2014, almost 1.5 million people died from tuberculosis (TB), and an estimated 9.6 million developed the disease worldwide [1]. TB is now the leading cause of death from an infectious disease, along with HIV/AIDS. HIV-positive patients are at high risk for opportunistic infections (OIs) such as TB. HIV infection and HIV-associated immunodeficiency are strong risk factors for TB, and in many low-income countries TB is the most common AIDS-defining illness [2–4]. Combination antiretroviral therapy (ART) has substantially improved the prognosis of HIV infection, and

reduced the risk of OIs in both industrialized and low-income countries [5,6].

However, the risk of activation of latent TB and progression to clinical disease remains high in HIV-positive patients with high CD4 cells, possibly because HIV replication itself is associated with impaired protection against progression to active TB [7]. Indeed, patients with high levels of HIV replication appear to have a greater risk of OIs compared to patients on ART with suppressed HIV-replication and similar CD4 cell counts [8–10]. There is increasing evidence that ongoing HIV replication causes chronic immune

activation, including the release of cytokines, and increased cell turnover, which in turn leads to a shift in lymphocyte phenotypes and to a reduced quality of the immune response [11].

Previous studies of the association of HIV-RNA viral load with TB incidence were conducted in high-income settings with a low TB incidence, and had a relatively small sample size. We analysed a large collaborative cohort of HIV-positive patients from three different ART programmes in South Africa to study the role of ongoing HIV replication as an independent risk factor for TB after starting ART.

## Methods

We included data from patients  $\geq 16$  years of age starting ART between 1 January 2000 and 31 December 2014 in three South African treatment programmes that participate in the International Epidemiology Databases to Evaluate AIDS in Southern Africa (IeDEA-SA, [www.iedea-sa.org](http://www.iedea-sa.org)) [12], and also systematically record OIs and HIV viral load (Khayelitsha and Tygerberg in the Western Cape, Themba Lethu Clinic in Johannesburg). Data are collected as part of routine monitoring at enrolment and each follow-up visit, including TB symptoms. All study sites have local institutional review board or Ethics Committee approval to collect data and participate in IeDEA-SA. Children were excluded as they present a different study population, as well as patients with a previous TB episode. The selection of eligible patients is shown in [Figure 1](#).

An incident TB episode was defined as a diagnosis and treatment start of TB (pulmonary or extrapulmonary) one month after ART initiation or later, as reported by each site [13,14]. Person-time was calculated from ART initiation (baseline) to TB diagnosis, death or last follow-up information. To account for missing values of CD4 cell count and HIV-RNA viral load at baseline and during follow-up, we generated 50 imputed datasets assuming missing at random using the MICE and Amelia II package in R [15]. The number of missing values are shown in Additional File 1. The imputation model included age, sex, CD4 count, viral load, observation time, and WHO clinical stage [16]. Results were combined with Rubin's rules [17]. For the purpose of the imputation process, patients were expected to have laboratory tests every four months until the time of TB diagnosis, death or last follow-up information.

We used chi-squared tests for differences between groups in binary variables, and the Wilcoxon rank-sum test for continuous variables. We used parametric survival models to assess TB incidence stratified by levels of baseline CD4 cell count (0–99, 100–349,  $\geq 350$  cells/ $\mu$ L, unknown) and HIV-RNA (0–999, 1,000–9,999,  $\geq 10,000$  copies/mL, unknown). We estimated rate ratios adjusted for age, sex, baseline viral loads, CD4 cell counts, and WHO clinical stage, taking into account clustering by cohorts (ART programmes). Rate ratios were also calculated using a complete case dataset (without missing CD4 cell count and HIV viral load at start of ART). In addition, interactions between CD4 count and HIV-RNA on TB incidence were assessed by including interaction terms in the regression model. Finally, we used Poisson generalized additive regression models

with time-updated CD4 cell counts and HIV-RNA values, smoothed by a regression spline for CD4 and HIV-RNA, and adjusting for age and sex.

All analyses were performed in Stata version 14.1 (Stata Corporation, College Station, TX, USA) and R 12.1 (R Development Core Team, Vienna, Austria).

## Results


We analysed 44,260 patients with a median follow-up time of 2.70 years (interquartile range [IQR] 0.99–5.02); 3,819 patients (8.6%) had an incident TB diagnosis one month after starting ART or later (median 1.05 years, IQR [0.33, 2.66]). Median age at ART initiation (baseline) was 34 years (IQR 28–41 years), and 30,675 (69.3%) patients were female. Baseline median CD4 cell count was 156 cells/ $\mu$ L (IQR 79–229) and the median HIV-RNA viral load was 58,000 copies/mL (IQR 6,000–240,000) ([Table 1](#)). Most patients were on an ART regimen based on two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor (41,104 – 92.9%); 3,156 (7.1%) were on other regimens. Patients who developed TB had lower baseline median CD4 cell counts (117 versus 161 cells/ $\mu$ L), higher baseline median HIV viral loads (111,000 versus 50,000 copies/mL), and more advanced disease (WHO clinical stage III/IV 22.2% versus 15.6%) compared to other patients, whereas distributions of age and sex were similar ([Table 1](#)).

During 146,008 person-years, TB incidence was 26.2 per 1,000 person-years (95% confidence interval [CI] 25.3–27.0). TB incidence was higher in patients with high HIV-RNA compared to patients with lower HIV-RNA, with this difference being almost fourfold in the intermediate and highest CD4 stratum ([Figure 2](#)). When comparing the highest with the lowest CD4 cell group ( $\geq 350$  versus  $< 100$  cells/ $\mu$ L), the adjusted rate ratio for TB was 0.52 (95% CI 0.39–0.69,  $p < 0.001$ ), as shown in [Table 2](#). Comparing the highest with lowest HIV-RNA group (0–999 versus  $\geq 10,000$  copies/mL), the adjusted rate ratio for TB was 1.42 (95% CI 1.19–1.69,  $p < 0.001$ ). There was no statistically significant interaction between the effects of CD4 count and HIV-RNA on TB incidence ( $p$ -value from test for interaction: 0.24). The complete case analysis showed similar results ([Table 2](#)).

Time-updated analyses for CD4 cell count and HIV-RNA viral load fixed at different HIV-RNA levels confirmed the effect of viral load on the risk of TB ([Figure 3](#)), although CIs were wide in the range of higher CD4 cell counts. Similar results were obtained in a complete case analysis (Additional file 2, [Figure](#)). [Figure 4](#) shows a three-dimensional model of CD4 cell count and HIV-RNA to predict TB incidence after starting ART.

## Discussion

We analysed HIV-positive patients starting ART in three large HIV treatment programmes in South Africa. We found that HIV-positive TB patients with ongoing HIV replication as determined by plasma HIV viral loads are at increased risk for TB.



**Figure 1. Selection of the study population.**  
 ART: antiretroviral treatment; TB: tuberculosis.

Viral replication is an independent risk factor for TB during ART, regardless of CD4 cell counts. This is supported by both the analysis of TB incidence at baseline, as well as the analysis of time-updated CD4 cell counts and HIV-RNA viral loads on a continuous scale. CD4 cell counts in peripheral blood are a useful marker of immune competence in HIV-positive patients, but ongoing HIV replication as measured by the plasma HIV-RNA viral load has previously been suggested as a CD4 cell count independent risk factor


for OIs in patients on ART [7–9]. Even though ART reduces the risk of TB substantially, the risk remains high in HIV-positive people, even in countries with low TB transmission [18,19].

Our findings show that HIV replication is a useful tool to predict the risk for TB after starting ART. This supports the current WHO guidelines to scale-up viral load testing in low-income countries to monitor adherence to ART and treatment failure. The recent results from clinical trials and the

**Table 1. Baseline characteristics of patients in antiretroviral treatment (ART) programmes included in the study, overall and stratified by tuberculosis (TB) status**

Characteristic	All	Incident TB	No TB	p-Value
	n = 44,260	n = 3,819	n = 40,441	
Age at start of ART, median (IQR), years	34 (28–41)	33 (28–40)	34 (29–41)	0.015
Female sex, n (%)	30,675 (69.4)	2,448 (64.1)	28,227 (69.8)	<0.001
Site of TB, n (%)	3,819	3,819	-	
Pulmonary	2,797 (73.2)	2,797 (73.2)	-	
Extrapulmonary	1,022 (26.8)	1,022 (26.8)	-	
CD4 cell count at ART start, median (IQR), cells/ $\mu$ l	156 (79–229)	117 (55–180)	161 (82–233)	<0.001
No. of patients with value (%)	36,773 (83.1)	3,227 (84.5)	33,546 (83.0)	
Imputed values	175 (96–270)	130 (67–205)	179 (100–277)	
HIV RNA viral load at ART start, median (IQR), copies/mL	58,000	111,000	50,000	<0.001
(6,000–240,000)		(32,000–370,000)	(3,900–220,000)	
No. of patients with value (%)	7,205 (16.3)	924 (24.2)	6,281 (15.5)	
Imputed values	36,013	107,102	27,472	
(1,613–418,771)		(3,526–500,000)	(1,613–365,717)	
WHO clinical stage, n (%)				
No. of patients with value (%)	15,711 (35.5)	1,021 (26.7)	14,690 (36.3)	<0.001
I and II	13,187 (84.0)	794 (77.7)	12,393 (84.4)	
III	2,041 (13.0)	166 (16.3)	1,875 (12.7)	
IV	483 (3.0)	61 (5.9)	422 (2.9)	
Imputed values for stage IV, %	1,218 (2.8)	196 (5.1)	1020 (2.3)	
Treatment programme, n (%)	44,260			<0.001
Themba Lethu	15,711 (35.5)	1,021 (26.7)	22,412 (55.4)	
Khayelitsha	24,935 (56.3)	2,523 (66.1)	14,690 (36.3)	
Tygerberg	3,614 (8.2)	275 (7.2)	3,339 (8.3)	

IQR: interquartile range



**Figure 2. Crude incidence rates (per 1,000 person-years) of tuberculosis after starting antiretroviral therapy, by baseline levels of CD4 cell count (cells/ $\mu$ l) and HIV-RNA viral load (copies/mL).**

Based on 44,260 HIV-positive patients. Bars correspond to 95% confidence intervals. Unknown HIV-RNA viral load categories are shown in blue (unknown CD4 cell count category not shown).


**Table 2. Adjusted rate ratios for tuberculosis (TB) according to CD4 cell count and HIV-RNA viral load at start of antiretroviral therapy (ART).**

Characteristic	All patients	Patients with incident TB	Imputed dataset analysis (n = 44,260)		Complete case dataset analysis (n = 6,707)	
	n = 44,260	n = 3,819 (8.6%)	Adjusted rate ratio (95% CI)	p-Value	Adjusted rate ratio (95% CI)	p-Value
CD4 cell count at ART start, cells/ $\mu$ l, n (%)				0.001		<0.001
0–99	11,506	1,388 (12.1)	1		1	
100–349	23,116	1,800 (7.8)	0.78 (0.67–0.92)		0.85 (0.82–0.88)	
$\geq$ 350	2,151	39 (1.8)	0.49 (0.36–0.66)		0.52 (0.30–0.93)	
HIV RNA viral load at ART start, copies/ml, n (%)				<0.001		<0.001
0–999	1,336	54 (4.0)	1		1	
1,000–9,999	710	57 (8.0)	1.23 (1.08–1.41)		1.43 (1.00–2.04)	
$\geq$ 10,000	5,159	813 (15.8)	1.41 (1.17–1.71)		2.01 (1.35–2.99)	
Age at start of ART, years	-	-	0.99 (0.98–1.0)	0.02	0.99 (0.97–1.00)	0.12
Sex				<0.001		<0.001
Male	13,585	1,371 (10.1)	1		1	
Female	30,675	2,448 (8.0)	0.76 (0.70–0.82)		0.78 (0.70–0.87)	
WHO clinical stage, n (%)				<0.001		<0.001
I and II	27,553	1,693 (6.1)	1		1	
III and IV	15,664	2,060 (13.2)	1.84 (1.76–1.94)		1.98 (1.59–2.47)	

The complete case dataset included patients without missing CD4 cell count and HIV-RNA at start of ART.

Model adjusted for age, sex, baseline viral loads, CD4 cell counts, and WHO clinical stage, taking into account clustering by cohorts (ART programmes).


95% CI: 95% confidence interval; IQR, interquartile range.



**Figure 3. Influence of current CD4 cell count, and current HIV-RNA viral load on tuberculosis (TB) incidence. Models of TB incidence after starting antiretroviral therapy (ART) per 1,000 person-years, CD4 cell count (cells/ $\mu$ l), and HIV-RNA viral load (copies/mL) after imputation of missing CD4 cell counts and viral loads at start of ART and during follow-up, based on 44,260 HIV-positive patients. Curves represent patients with different HIV-RNA viral loads. (a) Viral load 100 vs. 10,000 copies/mL; (b) 100 vs. 100,000 copies/mL.**

newly issued WHO guidelines state that ART should be initiated in all people diagnosed with HIV, regardless of CD4 cell counts at time of diagnosis [20]. However, many obstacles will need to be overcome before the new

guidelines will be implemented widely in sub-Saharan Africa which carries the highest HIV-TB burden [21]. Until recently, ART was not generally recommended in HIV-positive patients with CD4 cell counts above 500 cells/ $\mu$ L.



**Figure 4.** Three-dimensional model of current CD4 cell count (cells/ $\mu$ l), and HIV-RNA viral load (copies/mL) as predictors of tuberculosis (TB) incidence per 1,000 person-years after starting antiretroviral therapy (ART). Based on 44,260 HIV-positive patients after imputation of missing CD4 cell counts and HIV-RNA viral loads at start of ART and during follow-up. TB: tuberculosis.

However, the risk of activating latent TB infection and fast progression to disease remains high in the group of HIV-positive patients with higher CD4 cells, particularly in patients with high HIV-RNA viral loads as shown here. This could possibly be explained because HIV replication itself is associated with a distorted immune system and impaired protection against progression to disease [11]. These mechanisms include increased cell turnover, activation, differentiation, and cytokine release [11]. This is demonstrated by the fact that the immune response to vaccines such as yellow fever is reduced in patients with ongoing HIV replication [22].

HIV-positive patients with high HIV viral loads are at high risk of TB, regardless of CD4 cell counts, and may therefore particularly benefit from administration of isoniazid preventive therapy (IPT) to reduce the risk of developing TB. Therefore, HIV viral load monitoring in patients on ART can be an important tool to identify patients at highest risk of TB who would benefit most from long-term IPT. In high TB incidence regions, the scale-up of IPT to prevent progression from infection to TB disease is still challenging as shown in a survey among ART programmes of the IeDEA collaboration [23]. In addition, randomized clinical trials showed a limited efficacy of IPT, and the benefit of IPT might be only short-term in high TB prevalence settings with ongoing TB transmission and a high risk of re-exposure [24–26]. Individuals with proven TB infection (e.g., tuberculin skin test positive) appear to benefit most from IPT [26], but reliable testing for latent TB is difficult to perform in low-income settings. However, IPT could be an additional tool that complements early start of ART to further reduce the risk of TB [27,28].

A limitation of our study was the missing values for HIV-RNA which is not routinely performed at start of ART in South Africa. We addressed this by imputing HIV-RNA values at baseline and during follow-up. Another limitation is potential residual confounding by factors not captured in

the dataset, and the potential under-ascertainment of TB. However, we restricted our study to cohorts that systematically collect information on OIs. Another limitation was the heterogeneity between the included ART programmes [13]. To address this, we also calculated risk ratios, adjusted for the most important confounding factors.

## Conclusions

We found that ongoing HIV replication is an important risk factor for TB, regardless of CD4 cell counts. Furthermore, viral load values in addition to CD4 cell counts should be used to predict the risk of TB after starting ART and during follow-up. Our study underlines the importance of early start of ART in HIV-positive persons with a high viral load and continuous retention on effective ART. Further studies are needed during the ongoing scale-up phase of universal HIV-RNA viral load monitoring to document its usefulness to predict the risk of TB after starting ART and the effectiveness of IPT.

## Authors' affiliations

<sup>1</sup>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; <sup>2</sup>Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland; <sup>3</sup>University of Basel, Basel, Switzerland; <sup>4</sup>Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland; <sup>5</sup>Khayelitsha ART Programme, Médecins Sans Frontières, Cape Town, South Africa; <sup>6</sup>Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; <sup>7</sup>Departments of Epidemiology and Global Health, Boston University, Boston, MA, USA; <sup>8</sup>Division of Infectious Diseases, Department of Medicine, University of Stellenbosch and Tygerberg Hospital, Cape Town, South Africa; <sup>9</sup>Centre for Infectious Disease Epidemiology and Research (CIDER), School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

## Competing interest

The authors have no competing interests to declare.

#### Authors' contribution

Conception and design: LF, AA, MZ, HF, MAD, ME. Acquisition of data: AB, MPF, HP, MAD. Analyses: AA, KZ, MB, MZ. Drafting the manuscript: LF, AA, AB, MPF, HP, KZ, MB, MZ, HF, MAD, ME. Final approval of the manuscript: LF, AA, AB, MPF, HP, KZ, MB, MZ, HF, MAD, ME. All authors have read and approved the final version.

#### Acknowledgements

We thank all patients whose data were used in this study. We also would like to thank all who contributed to recording and entering data as well as preparing and sending it to the leDEA Southern Africa collaboration.

**Site investigators and cohorts:** Gary Maartens, Aid for AIDS, South Africa; Christopher J Hoffmann, Aurum Institute for Health Research, South Africa; Michael Vinikoor, Centre for Infectious Disease Research in Zambia (CIDRZ), Zambia; Eusebio Macete, Centro de Investigacao em Saude de Manhica (CISM), Mozambique; Daniela Garone, Dignitas, Malawi; Robin Wood, Gugulethu ART Programme, South Africa; Shobna Shawry, Harriet Shezi Clinic, South Africa; Frank Tanser, Africa Centre for Health & Population Studies (Hlabisa), South Africa; Andrew Boule, Khayelitsha ART Programme, South Africa; Geoffrey Fatti, Kheth'Impilo, South Africa; Sam Phiri, Lighthouse Clinic, Malawi; Janet Giddy, McCord Hospital, South Africa; Cleophas Chimbetete, Newlands Clinic, Zimbabwe; Kennedy Malisita, Queen Elizabeth Hospital, Malawi; Karl Technau, Rahima Moosa Mother and Child Hospital, South Africa; Brian Eley, Red Cross Children's Hospital, South Africa; Christiane Fritz, SolidarMed Lesotho; Michael Hobbins, SolidarMed Mozambique; Kamelia Kamenova, SolidarMed Zimbabwe, Matthew P Fox, Themba Lethu Clinic, South Africa; Hans Prozesky, Tygerberg Academic Hospital, South Africa.

**Data centres:** Nanina Anderegg, Marie Ballif, Zofia Baranczuk, Julia Bohlius, Cam Ha Dao Ostinelli, Matthias Egger, Janne Estill, Lukas Fenner, Kelly Goodwin, Olivia Keiser, Justine Locher, Eliane Rohner, Luisa Salazar-Vizcaya, Adrian Spörri, Gilles Wandeler, Elizabeth Zaniewski, Kathrin Zürcher, Institute of Social and Preventive Medicine, University of Bern, Switzerland; Andrew Boule, Morna Cornell, Mary-Ann Davies, Nicola Maxwell, Landon Myer, Leigh Johnson, Gem Patten, Michael Schomaker, Priscilla Tsondai, School of Public Health and Family Medicine, University of Cape Town, South Africa.

#### Funding

Research reported in this publication was supported by the US National Institutes of Health (NIAID, NICHD, NCI, NIMH, and NIDA) under Award Number U01AI069924 (PI: Egger and Davies) and the Swiss National Science Foundation (grant number 324730\_149792, PI: Furrer). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

#### References

- [1] World Health Organization. Global tuberculosis report 2014. World Health Organization Document. 2014;WHO/HTM/TB/2014.08:1–149.
- [2] Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. *Ann Intern Med.* 1996;124(7):633–42.
- [3] Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloi V, Clayton TC, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. *Clin Infect Dis.* 2002;34(9):1251–58.
- [4] Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. *Clin Infect Dis.* 2003;36(5):652–62.
- [5] Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. *Swiss HIV Cohort Study.* *Lancet.* 1999;353(9156):863–68.
- [6] Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boule A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet.* 2006;367(9513):817–24.

- [7] Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, et al. Risk of tuberculosis following HIV seroconversion in high-income countries. *Thorax.* 2013;68(3):207–13.
- [8] Kaplan JE, Hanson DL, Jones JL, Dworkin MS. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. *AIDS.* 2001;15(14):1831–36.
- [9] Swindells S, Evans S, Zackin R, Goldman M, Haubrich R, Filler SG, et al. Predictive value of HIV-1 viral load on risk for opportunistic infection. *J Acquir Immune Defic Syndr.* 2002;30(2):154–58.
- [10] The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Is it safe to discontinue primary *Pneumocystis jirovecii* pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/uL? *Clin Infect Dis.* 2010;51(5):611–19.
- [11] Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. *Annu Rev Pathol.* 2011;6:223–48.
- [12] Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al. Cohort profile: the international epidemiological databases to evaluate AIDS (leDEA) in sub-Saharan Africa. *Int J Epidemiol.* 2012;41(5):1256–64.
- [13] Fenner L, Ballif M, Graber C, Nhandu V, Dusingize JC, Cortes CP, et al. Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. *PLoS One.* 2013;8(10):e77697.
- [14] Fenner L, Reid SE, Fox MP, Garone D, Wellington M, Prozesky H, et al. Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. *Trop Med Int Health.* 2013;18(2):194–98.
- [15] Honaker J, King G, Blackwell M. 2012. Amelia II: a program for missing data, R package version 1.5. Available from: <http://gkingharvardedu/amelia/>
- [16] Honaker J, King G. What to do about missing values in time-series cross-section data. *Am J Polit Science.* 2010;54(2):561–81.
- [17] Rubin DB. Multiple imputation after 18+ years. *J Am Stat Assoc.* 1996;91(434):473–89.
- [18] Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. *Lancet.* 2002;359(9323):2059–64.
- [19] Girardi E, Sabin CA, D'Arminio MA, Hogg B, Phillips AN, Gill MJ, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. *Clin Infect Dis.* 2005;41(12):1772–82.
- [20] Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med.* 2015;373(9):795–807.
- [21] De Cock KM, El-Sadr WM. From START to finish: implications of the START study. *Lancet Infect Dis.* 2016;16(1):13–14.
- [22] Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. *Clin Infect Dis.* 2009;48(5):659–66.
- [23] Charles MK, Lindegren ML, Wester CW, Blevins M, Sterling TR, Dung NT, et al. Implementation of tuberculosis intensive case finding, isoniazid preventive therapy, and infection control ("Three I's") and HIV-tuberculosis service integration in lower income countries. *PLoS One.* 2016;11(4):e0153243.
- [24] Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, et al. Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. *AIDS.* 2015;29:351–56.
- [25] Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. *N Engl J Med.* 2011;365:21–31.
- [26] Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2011;377:1588–98.
- [27] Rangaka MX, Wilkinson RJ, Boule A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. *Lancet.* 2014;384:682–90.
- [28] Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. *AIDS.* 2009;23:631–36.